Abnova mouse monoclonal LMTK3 antibody H00114783-M02 was validated in knockout human breast cancer cell line
DOI
//dx.doi.org/10.13070/ko.en.6.1586
Date
2016-08-30

This is a knockout-validated antibody summary, based on the publication "LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Company: Abnova

Antibody: LMTK3

Catalog number: H00114783-M02

Summary

Mouse IgG1 kappa monoclonal antibody raised against a partial recombinant LMTK3 human protein. It detects human protein and has been used for western blot and as capture antibody in ELISA.

Abnova mouse monoclonal LMTK3 antibody H00114783-M02  was validated in knockout human breast cancer cell line figure 1
Figure 1. Western blotting of LMTK3 protein from LMTK3 CRISPR knockout MDA-MB-231 cell clones and control cells, from figure S1 [1].
Validation Method

Western blotting.

Sample

LMTK3 CRISPR knockout MDA-MB-231 cells. LMTK3 exon 12 was deleted from MDA-MB-231 cells through CRISPR. The deletion was confirmed by PCR and DNA sequencing. Cells were lysed in RIPA buffer (#R0278, SIGMA-ALDRICH) supplemented with protease and phosphatase inhibitors.

Clone note

The same clone (2H6) is sold as Abnova H00114783-M02, H00114783-M02A; Sigma-Aldrich WH0114783M2.

References
  1. Xu Y, Zhang H, Nguyen V, Angelopoulos N, Nunes J, Reid A, et al. LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Rep. 2015;12:837-49 pubmed publisher